PON1基因rs854572单核苷酸多态性与氯吡格雷抵抗的相关性研究

被引:14
作者
刘滕飞 [1 ]
张效林 [2 ]
蔡文芝 [1 ]
闫承慧 [2 ]
梁振洋 [2 ]
孙莹 [2 ]
韩雅玲 [2 ]
机构
[1] 辽宁医学院心血管内科
[2] 沈阳军区总医院心血管内科
关键词
氯吡格雷抵抗; 对氧磷酶1; 多态性,单核苷酸;
D O I
暂无
中图分类号
R541.4 [冠状动脉(粥样)硬化性心脏病(冠心病)];
学科分类号
摘要
目的探讨对氧磷酶1(PON1)基因rs854572单核苷酸多态性与氯吡格雷抵抗(CR)发生的相关性。方法采用病例-对照研究的方法,共入选850例沈阳军区总医院冠心病住院患者,采用光学比浊法测定20μmol/L二磷酸腺苷(ADP)诱导的残余血小板聚集率(RPA),当RPA≥70%时,即定义为CR。将入选患者分为CR组(n=215)和非氯吡格雷抵抗(NCR)组(n=635),采用焦磷酸测序法测定PON1基因rs854572单核苷酸多态性的基因型及等位基因分布频率。结果 PON1基因rs854572多态位点在两组间基因型分布频率皆符合Hardy-Weinberg平衡定律,三种基因型(CC、CG和GG)分布频率在CR组和NCR组分别为23.7%、49.3%、27.0%和24.1%、50.2%、25.7%,三种基因型在两组间分布频率差异无统计学意义(P=0.93)。C、G等位基因分布频率在两组间差异亦无统计学意义(P=0.763)。Logistic回归校正性别、年龄、体重指数、吸烟、高血压、高脂血症及糖尿病等冠心病易患因素后,PON1基因rs854572单核苷酸多态性仍与冠心病患者CR的发生无相关关系。结论 PON1基因单核苷酸多态位点rs854572与冠心病患者CR的发生无关。
引用
收藏
页码:982 / 986
页数:5
相关论文
共 11 条
  • [1] ABCB1基因单核苷酸多态性rs2235048与氯吡格雷抵抗的相关关系
    白净
    张效林
    梁振洋
    孙莹
    冯雪瑶
    韩雅玲
    [J]. 现代生物医学进展, 2012, 12 (04) : 601 - 604
  • [2] 新型抗血小板药物临床研究进展
    万文辉
    钱晓明
    [J]. 中国实用内科杂志, 2011, 31 (10) : 796 - 798
  • [3] 冠状动脉介入治疗后血管再狭窄的药物防治进展
    伍前发
    张宜青
    林青
    [J]. 武警医学院学报, 2010, 19 (09) : 753 - 756
  • [4] 细胞色素P450 3A4 894C>T位点基因多态性与氯吡格雷抵抗的关系
    韩雅玲
    麦晓燕
    李毅
    张效林
    郭亮
    闫承慧
    [J]. 解放军医学杂志, 2008, (08) : 939 - 942
  • [5] Genetic determinants of on-clopidogrel high platelet reactivity
    Campo, Gianluca
    Miccoli, Matteo
    Tebaldi, Matteo
    Marchesini, Jlenia
    Fileti, Luca
    Monti, Monia
    Valgimigli, Marco
    Ferrari, Roberto
    [J]. PLATELETS, 2011, 22 (06) : 399 - 407
  • [6] The relation between platelet reactivity and glycemic control in diabetic patients with cardiovascular disease on maintenance aspirin and clopidogrel therapy
    Singla, Anand
    Antonino, Mark J.
    Bliden, Kevin P.
    Tantry, Udaya S.
    Gurbel, Paul A.
    [J]. AMERICAN HEART JOURNAL, 2009, 158 (05) : 784.e1 - 784.e6
  • [7] Cardiovascular Death and Nonfatal Myocardial Infarction in Acute Coronary Syndrome Patients Receiving Coronary Stenting Are Predicted by Residual Platelet Reactivity to ADP Detected by a Point-of-Care Assay: A 12-Month Follow-Up[J] . Rossella Marcucci,Anna Maria Gori,Rita Paniccia,Betti Giusti,Serafina Valente,Cristina Giglioli,Piergiovanni Buonamici,David Antoniucci,Rosanna Abbate,Gian Franco Gensini.Circulation . 2009 (2)
  • [8] Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial[J] . Stephen D Wiviott,Eugene Braunwald,Carolyn H McCabe,Ivan Horvath,Matyas Keltai,Jean-Paul R Herrman,Frans Van de Werf,William E Downey,Benjamin M Scirica,Sabina A Murphy,Elliott M Antman.The Lancet . 2008 (9621)
  • [9] Impact of body mass index on platelet aggregation after administration of a high loading dose of 600 mg of Clopidogrel before percutaneous coronary intervention
    Sibbing, Dirk
    von Beckerath, Olga
    Schoemig, Albert
    Kastrati, Adnan
    von Beckerath, Nicolas
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 2007, 100 (02) : 203 - 205
  • [10] Aspirin and Clopidogrel Drug Response in Patients Undergoing Percutaneous Coronary Intervention[J] . Eli I. Lev,Rajnikant T. Patel,Kelly J. Maresh,Sasidhar Guthikonda,Juan Granada,Timothy DeLao,Paul F. Bray,Neal S. Kleiman.Journal of the American College of Cardiology . 2006 (1)